Background:
The RA modern treatment approaches are based on "aggressive therapy", which aims at suppressing autoimmune inflammation and prevent joint destructionsat the early stages of the disease. Objectives: To evaluate the effectiveness and tolerability of the triple combination therapy with methotrexate, leflunomide and methylprednisolone in patients with rheumatoid arthritis. Methods: The study included 150 patients with rheumatoid arthritis. As a result of randomization, 50 patients received triple combination therapy (methotrexate +methylprednisolone+leflunomide), 50 patients with monotherapy with methotrexate, leflunomide 50 others. As a result all patient groups were comparable after all clinical and demographic indices. Results: Our results showed that triple therapy is very effective in treating patients with RA. A significant improvement on the criteria of the AAR (ACR>50) at the end of the study was observed in most patients receiving methotrexate, leflunomide and methylprednisolone. This is confirmed statistically and clinically positive dynamics significantly in almost all indicators used of efficacy (pain, stiffness, number of tender and swollen joints, the activity of AR, the value VSH index functional HAQ) In addition, the use of triple therapy decreased average dose simultaneous use of glucocorticosteroids daily (from 5.0 to 2.5 mg) and 76% of patients canceled anti-inflammatory non-steroid drugs. Conclusions: After randomized trial data lasting 24 months based triple therapy (methotrexate, leflunomide and methylprednisolone) was highly effective in patients with high RA activity. A significant improvement according to the criteria of ACR (ACR>50) was obtained in 31 of 39 patients (79.48%), including the nine patients (23.07%) had developed clinical remission. Administration of the basic triple therapy was characterized by a significant clinical effect ACR stability of>50. It was maintained during not less than 15 months of research in 28 (90.32%) of patients who received this treatment and only 3 of 11 (27.27%) patients who received methotrexate alone group and 8 in 10 (80%) who administered LF (p=0.039). Evidence recovery (ACR>50), as well as clinical remission was kept stable in all 28 patients that triple therapy was extended after the ending of basic research. Background: Rheumatoid arthritis is a autoimmune and multisystemic disease. However, the negative emotions of anxiety and depression are the ones that have been most addressed, and there is a close relationship between pain associated with pain. Hypnosis is one of the best documented behavioral interventions in the management of acute and chronic pain in adults. Objectives: To evaluate the efficacy of hypnotic analgesia for pain reduction and negative emotional states in patients with Rheumatoid Arthritis of the Guadalajara Civil Hospital Fray Antonio Alcalde Methods: The method was developed through a quasi-experimental study, in which had two groups: a control group (CG) of 11 patients and an experimental group (EG) of 17, the women's age group were developed between 18 and 65 years old diagnosed with arthritis. The medition of Pain was realized through an instrument called EVA, and for the case of the Anxiety and depression were through HAD, achieving the baseline of each one of the variables. The EG group attended three psychological sessions of Hypnosis, with intervals of one month each. In these sessions, the perception of pain with an EVA was measured at the beginning and at the end. After a month, the subsequent evaluation was performed, measuring the same initial variables, in order to make the comparison of the pre and pos. Results: The U of MANN Whitney was applied and it was identified that in the pre-test measurement, there were no statistically significant differences in the variables. However, in the pos measurement, differences were found in the patient's pain perception (z=-2.84, p<0.05), anxiety (z=-2.36, p<0.05) and The depression (z=-2.68, p<0.05). In addition, a Wilcoxon test was developed to determine differences between the pre-test score and the pos-test score in the EVA of each session. Statistically significant differences were found in the first session (Z=-3.65, p=0.001), second session (Z=-3.67, p=0.001) and third session (Z=-3.56, p=0.001). Conclusions: Hypnosis, as a behavioral technique, has shown efficacy in patients with chronic pain. In this research, a significant decrease in patients' perception of pain has been demonstrated. 
